Amarna's next-generation viral vector platform promises to transform treatment across many disease areas

Amarna Therapeutics, founded in 2008, is a privately held Biotech company that developed the SVac viral gene delivery vector platform, the key to the success of next stage gene and immune-therapies. SVac is safe, highly efficient, non-immunogenic and vector particles can be produced cost effectively in our SuperVero packaging cell line.

Because of its safety, efficacy and non-immunogenicity in humans our SVac platform has highly promising qualities for treating the major diseases of our time, creating opportunities to serve the major pharmaceutical markets.

Latest News


Oct 16, 2019
Amarna Therapeutics Raises €10 million to Progress lead Development Candidate into Clinical Trials and Appoints a new Supervisory Board

Quotes